VIVUS (STU:VIU1) Change In Receivables : €-0.91 Mil (TTM As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Change In Receivables?

VIVUS's change in receivables for the quarter that ended in Mar. 2020 was €-2.54 Mil. It means VIVUS's Accounts Receivable increased by €2.54 Mil from Dec. 2019 to Mar. 2020 .

VIVUS's change in receivables for the fiscal year that ended in Dec. 2019 was €2.57 Mil. It means VIVUS's Accounts Receivable declined by €2.57 Mil from Dec. 2018 to Dec. 2019 .

VIVUS's Accounts Receivable for the quarter that ended in Mar. 2020 was €22.38 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. VIVUS's Days Sales Outstanding for the three months ended in Mar. 2020 was 114.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. VIVUS's liquidation value for the three months ended in Mar. 2020 was €-200.46 Mil.

VIVUS Change In Receivables Historical Data

The historical data trend for VIVUS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Change In Receivables Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Change In Receivables

Get a 7-Day Free Trial

2.39

-0.46

-2.29

-11.80

2.57

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Change In Receivables	Get a 7-Day Free Trial															0.93	-0.01	0.46	1.18	-2.54

VIVUS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.91 Mil.

VIVUS (STU:VIU1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

VIVUS's Days Sales Outstanding for the quarter that ended in Mar. 2020 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	22.375	/	17.766	*	91
=	114.92

2. In Ben Graham's calculation of liquidation value, VIVUS's accounts receivable are only considered to be worth 75% of book value:

VIVUS's liquidation value for the quarter that ended in Mar. 2020 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	29.733	-	262.327	+	0.75 * 22.375	+	0.5 * 30.712
=	-200.46

VIVUS Change In Receivables Related Terms

Thank you for viewing the detailed overview of VIVUS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines